FDA
-
-
-
-
-
-
-
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on DiaMedica Therapeutics Inc. (DMAC)
-
-
-
-
-
-
-
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
-
-
-
-
-
-
-
DiaMedica Therapeutics (DMAC) Announces $11.8 Million Private Placement
-
-
-
-
-
-
-
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
-
-
-
-
-
-
-
DiaMedica Therapeutics Announces $37.5 Million Private Placement
-
-
-
-
-
-
-
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
-
329,631 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

